.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
In the current era of precision medicine, oncology clinicians frequently use prognostic vs predictive biomarkers to guide complex treatment decisions. For instance, circulating tumor DNA (ctDNA) helps monitor relapse risks or detect early progression. However, significant confusion persists regarding the utility of these markers at both the individual and clinical trial levels. This distinction is vital because a misunderstanding can lead to incorrect clinical inferences or misguided regulatory choices. Therefore, medical professionals must clearly differentiate between these two categories to optimize patient outcomes.
A prognostic biomarker provides essential information about the likely patient health outcome regardless of the therapy. Conversely, a predictive biomarker indicates the specific benefit a patient might receive from a particular treatment. Recent FDA reviews of the DESTINY-Breast11, SERENA-6, and IMvigor011 trials emphasize this complexity. While the FDA approved Enhertu based on pathological complete response (pCR) in DESTINY-Breast11, the SERENA-6 trial faced a different fate. Specifically, the Oncology Drug Advisory Committee (ODAC) voted against approval for camizestrant. They argued that the clinical benefit of switching therapy based on early ESR1 detection remained unproven. Consequently, identifying a marker as purely prognostic versus predictive is critical for validating surrogate endpoints in clinical trials.
Surrogate markers like ctDNA are transforming trial designs. The IMvigor011 trial demonstrated that atezolizumab significantly benefits patients with detectable ctDNA after surgery. This trial successfully used a biomarker-informed approach to refine patient selection. However, the SERENA-6 results highlight that simply detecting a mutation does not always predict a superior outcome from early intervention. Furthermore, clinical practice should only change when a biomarker is strong enough to serve as a reliable surrogate for overall survival. Clinicians should remain cautious when interpreting new biomarker data to ensure they reflect true clinical benefits for their patients.
Prognostic biomarkers provide information about the natural course of a disease. In contrast, predictive biomarkers identify patients more likely to respond to a specific therapeutic intervention.
The committee questioned if switching therapy upon ESR1 detection provided a clinically meaningful benefit compared to waiting for standard radiographic progression.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.
References
Pabani A et al. Critical Appraisal: Prognostic versus Predictive Surrogate Markers in Oncology. J Natl Cancer Inst. 2026 Jun 02. doi: undefined. PMID: 42226017.
U.S. Food and Drug Administration. Oncology Drug Advisory Committee Meeting Materials: SERENA-6 and Camizestrant. April 30, 2026.
AstraZeneca. Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor. April 2026.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
An appraisal of prognostic versus predictive biomarkers in oncology, focusing on recent FDA insights from DESTINY-Breast11 and SERENA-6 trials....
4 months ago
With India still adhering to 2009 air pollution benchmarks, the delayed NAAQS revision exposes populations to fine particulate matter far exceeding global safety limits. Clinicians face surging cardiopulmonary morbidity, emphasizing the urgent need for stringent, health-centered regulatory thresholds nationwide.
Today
India's leading assisted reproduction provider Indira IVF is in advanced talks to acquire a majority stake in Kerala's Sabine Hospital in a Rs 1,300 crore transaction. This strategic development highlights rising private equity interest, clinical consolidation, and changing demographic demands across reproductive medicine.
Today
Recent findings from the VESUVE study demonstrate that brain MRI detects intracranial lesions in over 76% of patients with infective endocarditis. Acute ischemic stroke and subarachnoid hemorrhage independently elevate six-month mortality, underscoring the critical prognostic utility of neuroimaging.
Yesterday
Modern 3D anthropometry reveals that pediatric leg growth ceases years before spinal elongation, exposing the clinical illusion of the classical Anderson-Green model. Learn how segmental growth dissociation improves surgical timing for epiphysiodesis in adolescent leg length discrepancy.
Yesterday
A meta-analysis of 18 studies reveals that bariatric surgery does not significantly alter circulating homocysteine levels, regardless of follow-up duration. Clinicians must maintain vigilance over post-surgical micronutrient supplementation to prevent hyperhomocysteinemia.
2 days back
